Pricing Reforms Prompt Canadian Business Rethink
Roche Has Withdrawn Tecentriq From HTA Processes
The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.
